RCS - ABCAM Plc - Webcast Interview with CEO
For best results when printing this announcement, please click on the link below:
http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20100719:nRSS5036Pa
RNS Number : 5036P
ABCAM Plc
19 July 2010
For immediate release 19 July 2010
RNS REACH
ABCAM PLC
("Abcam" or "the Company")
Webcast interview with Jonathan Milner, CEO
Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, is
pleased to announce that a webcast interview with Jonathan Milner, the Company's Chief Executive Officer, is ready to view
at the London Stock Exchange website:
www.londonstockexchange.com/growing-company-interviews
In the interview, Dr Milner discusses the dynamics of the antibody marketplace and gives an insight into Abcam's history
and operations, highlighting the importance of the internet to the Company's business model.
The interview marks the beginning of a series of webcasts hosted by the London Stock Exchange entitled Growing Company
Interviews. The interviews are designed to give investors a better understanding of selected companies quoted on the London
market.
For further information please contact:
Abcam + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
www.abcam.com
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic
Notes for editors
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with
subsidiaries in Cambridge, Massachusetts, Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under
the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies and related
products to academic and commercial users throughout the world. Product ordering is available through the Company's website
www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the
antibodies are sold under the Abcam brand name. Abcam's mission is to develop the largest catalogue of the best antibodies
in the world, with the vision of becoming a global leader in the wider protein detection and regulation markets. Abcam now
has a rapidly growing online catalogue and as at 30 June 2010 it contained 63,000 products, most of which are antibodies,
from over 250 suppliers. Abcam employs 270 staff in its four operating companies.
This information is provided by RNS
The company news service from the London Stock Exchange
back to RNS news